Rajani Ravi

Assistant Professor

19962018

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Rajani Ravi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Ravi, R., Noonan, K., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., Artemov, A. V., Wysocki, P. T., Mehra, R., Nimmagadda, S., Marchionni, L., Sidransky, D., Borrello, I. M., Izumchenko, E. & Bedi, A., Dec 1 2018, In : Nature Communications. 9, 1, 741.

Research output: Contribution to journalArticle

  • In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia

    Makarev, E., Schubert, A. D., Kanherkar, R. R., London, N., Teka, M., Ozerov, I., Lezhnina, K., Bedi, A., Ravi, R., Mehra, R., Hoque, M. O., Sloma, I., Gaykalova, D. A., Csoka, A. B., Sidransky, D., Zhavoronkov, A. & Izumchenko, E., Dec 4 2017, In : Cell Death Discovery. 3, 1, 17022.

    Research output: Contribution to journalArticle

    Open Access
  • Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors

    Izumchenko, E., Paz, K., Ciznadija, D., Sloma, I., Katz, A., Vasquez-Dunddel, D., Ben-Zvi, I., Stebbing, J., McGuire, W., Harris, W., Maki, R., Gaya, A., Bedi, A., Zacharoulis, S., Ravi, R., Wexler, L. H., Hoque, M., Rodriguez-Galindo, C., Pass, H., Peled, N. & 4 others, Davies, A., Morris, R., Hidalgo, M. & Sidransky, D., 2017, In : Annals of Oncology. 28, 10, p. 2595-2605 11 p.

    Research output: Contribution to journalArticle

  • SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells

    Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A., Fertig, E., Howard, J. D., Markovic, A., Bedi, A., Ravi, R., Perez, J., Le, Q. T., Kong, C. S., Jordan, R. C., Wang, H., Kang, H., Quon, H., Sidransky, D. & Chung, C. H., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 5162-5175 14 p.

    Research output: Contribution to journalArticle

  • A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

    Gilbert, J., Schell, M. J., Zhao, X., Murphy, B., Tanvetyanon, T., Leon, M. E., Hayes, D. N., Haigentz, M., Saba, N., Nieva, J., Bishop, J., Sidransky, D., Ravi, R., Bedi, A. & Chung, C. H., 2015, In : Oral Oncology. 51, 4, p. 376-382 7 p.

    Research output: Contribution to journalArticle